J. Perz

发表

Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis

H. Goldschmidt, A. Ho, A. Benner, 2008, Haematologica.

Risk Stratification in Cardiac Amyloidosis: Novel Approaches

H. Goldschmidt, P. Schnabel, H. Katus, 2005, Transplantation.

LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre

I. Lampert, D. Marin, J. Sanz, 2007, Bone Marrow Transplantation.

Mycobacterium haemophilum osteomyelitis in an AIDS patient.

A. Miller, J. Perz, M. Scully, 1992, New Jersey medicine : the journal of the Medical Society of New Jersey.

Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis.

H. Goldschmidt, H. Katus, U. Hegenbart, 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Non‐invasive predictors of survival in cardiac amyloidosis

H. Goldschmidt, P. Schnabel, H. Katus, 2007, European journal of heart failure.

High‐dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study

H. Goldschmidt, A. Ho, M. Zeier, 2004, British journal of haematology.

Impact of HLA class I and class II DNA high-resolution HLA typing on clinical outcome in adult unrelated stem cell transplantation after in vivo T-cell depletion with alemtuzumab.

J. Sanz, J. Apperley, J. Perz, 2007, Transplant immunology.

Clinical Study CD 4 + CD 25 highCD 127 low Regulatory T Cells in Peripheral Blood Are Not an Independent Factor for Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation

A. Ho, P. Dreger, U. Hegenbart, 2014 .

Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma.

A. Ho, J. Perz, 2008, Future oncology.

chronic myeloid leukemia immunotherapy in patients undergoing reduced intensity allografts for Post-transplant imatinib as a strategy to postpone the requirement for

C. Craddock, K. Piper, J. Byrne, 2013 .

Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.

T. Lipp, C. Schoch, H. Gschaidmeier, 2004, Blood.

Occurrence of donor-derived CLL 8 years after sibling donor SCT for CML

A. Ho, P. Dreger, M. Kneba, 2008, Bone Marrow Transplantation.

Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis

C. Mathias, A. Rahemtulla, J. Apperley, 2006, Bone Marrow Transplantation.

Tacrolimus (FK506) for Graft-versus-host Disease after Allogeneic Blood Stem Cell Transplantation for Hematologic Malignancies

T. Luft, A. Ho, J. Perz, 2004 .

(Ph+ ALL) outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia Early molecular response to posttransplantation imatinib determines

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2013 .

ALL) + (Ph Philadelphia-positive acute lymphoblastic leukemia + outcome in MRD Early molecular response to posttransplantation imatinib determines

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2009 .

Tips for severe hepatorenal syndrome in non-transplant cirrhotics: a new option?!

P. Raab, T. Sauerbruch, U. Spengler, 1998 .

[Interdisciplinary guidelines for diagnosis and therapy of extracerebral amyloidosis: issued by the German Society of Amyloid Diseases e. V. (www.amyloid.de)].

E. Hund, O. Sezer, W. Saeger, 2006, Medizinische Klinik.

Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.

C. Craddock, K. Piper, S. Siddique, 2007, Blood.

Ph Philadelphia-positive acute lymphoblastic leukemia + outcome in MRD Early molecular response to posttransplantation imatinib determines

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2005 .

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph^+ALL)

G. Lenz, A. Ganser, L. Kanz, 2006 .

CD4+CD25highCD127low Regulatory T Cells in Peripheral Blood Are Not an Independent Factor for Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation

A. Ho, P. Dreger, U. Hegenbart, 2012, TheScientificWorldJournal.

Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients

I. Lampert, K. Naresh, E. Terpos, 2006, Bone Marrow Transplantation.

Impact of HLA Class I and Class II DNA High-Resolution HLA Typing on Outcome in Adult Unrelated Stem Cell Transplantation after In Vivo T-Cell Depletion with CAMPATH 1H: A Single Centre Experience in 100 Patients.

J. Apperley, J. Perz, Richard Szydlo, 2005 .

Incidence of hyperthyroidism after unrelated donor allogeneic stem cell transplantation.

D. Marin, G. Williams, J. Apperley, 2007, Leukemia research.

Level of CD 20-expression and Efficacy of Rituximab Treatment in Patients with Resistant or Relapsing B-cell Prolymphocytic Leukemia and B-cell Chronic Lymphocytic Leukemia

A. Ho, M. Hensel, J. Topaly, 2002, Leukemia & lymphoma.

Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia.

D. Marin, J. Apperley, J. Perz, 2006, Haematologica.

[Interdisciplinary guidelines on diagnosis and treatment for extracerebral amyloidoses--published by the German Society of Amyloid Diseases (www.amyloid.de)].

E. Hund, O. Sezer, W. Saeger, 2006, Deutsche medizinische Wochenschrift.

A. Ho, P. Dreger, G. Otto, 2009, Haematologica.

Indications for High-Dose Chemotherapy with Autologous Stem Cell Support in Patients with Systemic Amyloid Light Chain Amyloidosis

H. Goldschmidt, A. Ho, E. Hund, 2005, Transplantation.

Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study

H. Schild, P. Raab, U. Spengler, 2000, Gut.

Long-term survival in a patient with AL amyloidosis after cardiac transplantation followed by autologous stem cell transplantation

H. Goldschmidt, H. Katus, F. Sack, 2006, Clinical Research in Cardiology.

No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement.

H. Goldschmidt, A. Ho, M. Zeier, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

G. Ledderose, H. Gschaidmeier, O. Ottmann, 2005, Blood.

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

H. Gschaidmeier, M. Schmid, O. Ottmann, 2006, Blood.

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

H. Gschaidmeier, M. Schmid, O. Ottmann, 2006, Blood.